Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 colchicine studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 31% 12 17,762 Improvement, Studies, Patients Relative Risk, 95% CI With exclusions 35% 11 17,449 Mortality 40% 10 17,373 Ventilation 32% 5 12,748 ICU admission 9% 2 299 Hospitalization 22% 2 4,588 Progression 55% 2 381 Recovery 20% 4 11,807 RCTs 14% 7 16,708 Peer-reviewed 46% 8 16,758 Late 31% 12 17,762 Colchicine for COVID-19 c19colchicine.com Nov 26, 2021 Favors colchicine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT​1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau​2 = 0.08; I​2 = 73.9% Late treatment 31% 0.69 [0.54-0.88] 1,256/8,681 1,419/9,081 31% improvement All studies 31% 0.69 [0.54-0.88] 1,256/8,681 1,419/9,081 31% improvement 12 colchicine COVID-19 studies c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.08; I​2 = 73.9%; Z = 3.02 Effect extraction pre-specified Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT​1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau​2 = 0.08; I​2 = 76.3% Late treatment 35% 0.65 [0.50-0.85] 1,240/8,629 1,334/8,820 35% improvement All studies 35% 0.65 [0.50-0.85] 1,240/8,629 1,334/8,820 35% improvement 11 colchicine COVID-19 studies after exclusions c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.08; I​2 = 76.3%; Z = 3.12 Effect extraction pre-specified Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] 122 (n) 140 (n) Pinzón 35% 0.65 [0.34-1.21] 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] 22/153 28/161 CT​1 Tau​2 = 0.17; I​2 = 74.5% Late treatment 40% 0.60 [0.42-0.86] 1,250/8,475 1,415/8,898 40% improvement All studies 40% 0.60 [0.42-0.86] 1,250/8,475 1,415/8,898 40% improvement 10 colchicine COVID-19 mortality results c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.17; I​2 = 74.5%; Z = 2.82 Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 82% 0.18 [0.02-1.50] 1/55 5/50 Improvement, RR [CI] Treatment Control Sandhu 53% 0.47 [0.33-0.67] 16/34 68/68 Tardif (DB RCT) 47% 0.53 [0.25-1.09] 11/2,235 21/2,253 Recovery C.. (RCT) -18% 1.18 [0.99-1.40] 259/3,815 228/3,962 Gaitán-Dua.. (RCT) 15% 0.85 [0.68-1.06] 27/136 27/140 CT​1 Tau​2 = 0.25; I​2 = 84.9% Late treatment 32% 0.68 [0.40-1.15] 314/6,275 349/6,473 32% improvement All studies 32% 0.68 [0.40-1.15] 314/6,275 349/6,473 32% improvement 5 colchicine COVID-19 mechanical ventilation results c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.25; I​2 = 84.9%; Z = 1.44 Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lopes (DB RCT) 50% 0.50 [0.10-2.56] 2/36 4/36 Improvement, RR [CI] Treatment Control Gaitán-Dua.. (RCT) 1% 0.99 [0.56-1.74] 19/113 18/114 CT​1 Tau​2 = 0.00; I​2 = 0.0% Late treatment 9% 0.91 [0.53-1.59] 21/149 22/150 9% improvement All studies 9% 0.91 [0.53-1.59] 21/149 22/150 9% improvement 2 colchicine COVID-19 ICU results c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.31 Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Improvement, RR [CI] Treatment Control Tardif (DB RCT) 20% 0.80 [0.61-1.03] hosp. 101/2,235 128/2,253 Tau​2 = 0.00; I​2 = 0.0% Late treatment 22% 0.78 [0.68-0.89] 101/2,285 128/2,303 22% improvement All studies 22% 0.78 [0.68-0.89] 101/2,285 128/2,303 22% improvement 2 colchicine COVID-19 hospitalization results c19colchicine.com Nov 26, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.72 Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT​1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau​2 = 0.16; I​2 = 71.9% Late treatment 37% 0.63 [0.45-0.88] 1,256/8,631 1,419/9,031 37% improvement All studies 37% 0.63 [0.45-0.88] 1,256/8,631 1,419/9,031 37% improvement 11 colchicine COVID-19 serious outcomes c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.16; I​2 = 71.9%; Z = 2.69 Effect extraction pre-specified Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brunetti (PSM) 73% 0.27 [0.08-0.89] no disch. 3/33 11/33 Improvement, RR [CI] Treatment Control Sandhu 42% 0.58 [0.40-0.85] no disch. 16/34 63/78 Recovery C.. (RCT) -2% 1.02 [0.97-1.06] no disch. 1,709/5,610 1,698/5,730 Dorward (RCT) 6% 0.94 [0.72-1.24] no recov. 156 (n) 133 (n) Tau​2 = 0.07; I​2 = 77.6% Late treatment 20% 0.80 [0.58-1.09] 1,728/5,833 1,772/5,974 20% improvement All studies 20% 0.80 [0.58-1.09] 1,728/5,833 1,772/5,974 20% improvement 4 colchicine COVID-19 recovery results c19colchicine.com Nov 26, 2021 Tau​2 = 0.07; I​2 = 77.6%; Z = 1.40 Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT​1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Tau​2 = 0.03; I​2 = 57.1% Late treatment 14% 0.86 [0.69-1.06] 1,207/8,295 1,237/8,413 14% improvement All studies 14% 0.86 [0.69-1.06] 1,207/8,295 1,237/8,413 14% improvement 7 colchicine COVID-19 Randomized Controlled Trials c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.03; I​2 = 57.1%; Z = 1.40 Effect extraction pre-specified Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] 0/36 2/36 Tardif (DB RCT) 44% 0.56 [0.19-1.67] 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] 1,173/5,610 1,190/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] 22/153 28/161 CT​1 Tau​2 = 0.02; I​2 = 15.2% Late treatment 8% 0.92 [0.72-1.17] 1,201/8,089 1,233/8,230 8% improvement All studies 8% 0.92 [0.72-1.17] 1,201/8,089 1,233/8,230 8% improvement 5 colchicine COVID-19 RCT mortality results c19colchicine.com Nov 26, 2021 1 CT: study uses combined treatmentTau​2 = 0.02; I​2 = 15.2%; Z = 0.69 Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Tau​2 = 0.23; I​2 = 79.0% Late treatment 46% 0.54 [0.34-0.85] 1,214/8,177 1,364/8,581 46% improvement All studies 46% 0.54 [0.34-0.85] 1,214/8,177 1,364/8,581 46% improvement 8 colchicine COVID-19 peer reviewed trials c19colchicine.com Nov 26, 2021 Tau​2 = 0.23; I​2 = 79.0%; Z = 2.65 Effect extraction pre-specified Favors colchicine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Deftereos (RCT) 82% 0.18 [0.02-1.50] ventilation 1/55 5/50 Deftereos (RCT) 87% 0.13 [0.01-0.97] progression 1/55 7/50 Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Lopes (DB RCT) 50% 0.50 [0.10-2.56] ICU 2/36 4/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Brunetti (PSM) 73% 0.27 [0.08-0.89] no disch. 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Sandhu 53% 0.47 [0.33-0.67] ventilation 16/34 68/68 Sandhu 42% 0.58 [0.40-0.85] no disch. 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Tardif (DB RCT) 47% 0.53 [0.25-1.09] ventilation 11/2,235 21/2,253 Tardif (DB RCT) 20% 0.80 [0.61-1.03] hosp. 101/2,235 128/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Recovery C.. (RCT) -18% 1.18 [0.99-1.40] ventilation 259/3,815 228/3,962 Recovery C.. (RCT) -2% 1.02 [0.96-1.09] int./death 1,344/5,342 1,343/5,469 Recovery C.. (RCT) -2% 1.02 [0.97-1.06] no disch. 1,709/5,610 1,698/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT​1 Gaitán-Dua.. (RCT) 15% 0.85 [0.68-1.06] ventilation 27/136 27/140 CT​1 Gaitán-Dua.. (RCT) 1% 0.99 [0.56-1.74] ICU 19/113 18/114 CT​1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Dorward (RCT) 22% 0.78 [0.30-1.73] hosp./death 6/156 119/1,145 Dorward (RCT) 6% 0.94 [0.79-1.11] progression 102/156 83/120 Dorward (RCT) 6% 0.94 [0.72-1.24] no recov. 156 (n) 133 (n) colchicine COVID-19 outcomes c19colchicine.com Nov 26, 2021 Favors colchicine Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit